Whole-body vibration ameliorates glial pathological changes in the hippocampus of hAPP transgenic mice, but does not affect plaque load.
Amyloid beta
J20 mice
Motor coordination
Neuroinflammation
Passive exercise
Journal
Behavioral and brain functions : BBF
ISSN: 1744-9081
Titre abrégé: Behav Brain Funct
Pays: England
ID NLM: 101245751
Informations de publication
Date de publication:
20 Mar 2023
20 Mar 2023
Historique:
received:
28
09
2022
accepted:
02
03
2023
entrez:
21
3
2023
pubmed:
22
3
2023
medline:
23
3
2023
Statut:
epublish
Résumé
Alzheimer's disease (AD) is the core cause of dementia in elderly populations. One of the main hallmarks of AD is extracellular amyloid beta (Aβ) accumulation (APP-pathology) associated with glial-mediated neuroinflammation. Whole-Body Vibration (WBV) is a passive form of exercise, but its effects on AD pathology are still unknown. Five months old male J20 mice (n = 26) and their wild type (WT) littermates (n = 24) were used to investigate the effect of WBV on amyloid pathology and the healthy brain. Both J20 and WT mice underwent WBV on a vibration platform or pseudo vibration treatment. The vibration intervention consisted of 2 WBV sessions of 10 min per day, five days per week for five consecutive weeks. After five weeks of WBV, the balance beam test was used to assess motor performance. Brain tissue was collected to quantify Aβ deposition and immunomarkers of astrocytes and microglia. J20 mice have a limited number of plaques at this relatively young age. Amyloid plaque load was not affected by WBV. Microglia activation based on IBA1-immunostaining was significantly increased in the J20 animals compared to the WT littermates, whereas CD68 expression was not significantly altered. WBV treatment was effective to ameliorate microglia activation based on morphology in both J20 and WT animals in the Dentate Gyrus, but not so in the other subregions. Furthermore, GFAP expression based on coverage was reduced in J20 pseudo-treated mice compared to the WT littermates and it was significantly reserved in the J20 WBV vs. pseudo-treated animals. Further, only for the WT animals a tendency of improved motor performance was observed in the WBV group compared to the pseudo vibration group. In accordance with the literature, we detected an early plaque load, reduced GFAP expression and increased microglia activity in J20 mice at the age of ~ 6 months. Our findings indicate that WBV has beneficial effects on the early progression of brain pathology. WBV restored, above all, the morphology of GFAP positive astrocytes to the WT level that could be considered the non-pathological and hence "healthy" level. Next experiments need to be performed to determine whether WBV is also affective in J20 mice of older age or other AD mouse models.
Sections du résumé
BACKGROUND
BACKGROUND
Alzheimer's disease (AD) is the core cause of dementia in elderly populations. One of the main hallmarks of AD is extracellular amyloid beta (Aβ) accumulation (APP-pathology) associated with glial-mediated neuroinflammation. Whole-Body Vibration (WBV) is a passive form of exercise, but its effects on AD pathology are still unknown.
METHODS
METHODS
Five months old male J20 mice (n = 26) and their wild type (WT) littermates (n = 24) were used to investigate the effect of WBV on amyloid pathology and the healthy brain. Both J20 and WT mice underwent WBV on a vibration platform or pseudo vibration treatment. The vibration intervention consisted of 2 WBV sessions of 10 min per day, five days per week for five consecutive weeks. After five weeks of WBV, the balance beam test was used to assess motor performance. Brain tissue was collected to quantify Aβ deposition and immunomarkers of astrocytes and microglia.
RESULTS
RESULTS
J20 mice have a limited number of plaques at this relatively young age. Amyloid plaque load was not affected by WBV. Microglia activation based on IBA1-immunostaining was significantly increased in the J20 animals compared to the WT littermates, whereas CD68 expression was not significantly altered. WBV treatment was effective to ameliorate microglia activation based on morphology in both J20 and WT animals in the Dentate Gyrus, but not so in the other subregions. Furthermore, GFAP expression based on coverage was reduced in J20 pseudo-treated mice compared to the WT littermates and it was significantly reserved in the J20 WBV vs. pseudo-treated animals. Further, only for the WT animals a tendency of improved motor performance was observed in the WBV group compared to the pseudo vibration group.
CONCLUSION
CONCLUSIONS
In accordance with the literature, we detected an early plaque load, reduced GFAP expression and increased microglia activity in J20 mice at the age of ~ 6 months. Our findings indicate that WBV has beneficial effects on the early progression of brain pathology. WBV restored, above all, the morphology of GFAP positive astrocytes to the WT level that could be considered the non-pathological and hence "healthy" level. Next experiments need to be performed to determine whether WBV is also affective in J20 mice of older age or other AD mouse models.
Identifiants
pubmed: 36941713
doi: 10.1186/s12993-023-00208-9
pii: 10.1186/s12993-023-00208-9
pmc: PMC10026461
doi:
Substances chimiques
Amyloid beta-Peptides
0
Amyloid beta-Protein Precursor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5Subventions
Organisme : ZonMW, Deltaplan Dementia and Alzheimer Nederland and Brain Foundation
ID : 733050303
Informations de copyright
© 2023. The Author(s).
Références
J Neurosci Methods. 2005 Jan 30;141(1):41-53
pubmed: 15585287
Metab Brain Dis. 2019 Feb;34(1):21-37
pubmed: 30443769
Clin Rehabil. 2014 Jan;28(1):59-68
pubmed: 23864514
Curr Neuropharmacol. 2018;16(5):508-518
pubmed: 28730967
Metab Brain Dis. 2018 Feb;33(1):15-25
pubmed: 28948448
Exp Neurol. 2013 Jan;239:28-37
pubmed: 23022919
Int J Mol Sci. 2018 Sep 13;19(9):
pubmed: 30217051
F1000Res. 2020 Jun 17;9:
pubmed: 32595943
Front Hum Neurosci. 2020 Oct 07;14:593672
pubmed: 33132889
Ageing Res Rev. 2008 Dec;7(4):319-29
pubmed: 18762281
J Musculoskelet Neuronal Interact. 2000 Sep;1(1):61-5
pubmed: 15758528
J Alzheimers Dis. 2019;70(3):681-690
pubmed: 31256137
Eur J Pharmacol. 2020 Nov 15;887:173554
pubmed: 32941929
J Neural Transm (Vienna). 2010 Aug;117(8):949-60
pubmed: 20552234
Int Arch Occup Environ Health. 2016 Feb;89(2):181-97
pubmed: 26012875
PLoS One. 2019 Jan 10;14(1):e0210036
pubmed: 30629631
J Neurosci. 2000 Jun 1;20(11):4050-8
pubmed: 10818140
Neurosci Lett. 2004 Oct 14;369(2):156-61
pubmed: 15450687
PLoS One. 2013;8(4):e59586
pubmed: 23560052
Exp Neurol. 2013 Oct;248:16-29
pubmed: 23707300
Neurosci Bull. 2018 Dec;34(6):912-920
pubmed: 30032411
Neuroscience. 1987 Aug;22(2):381-94
pubmed: 2823172
Cell Death Differ. 2009 Mar;16(3):378-85
pubmed: 19057621
Biology (Basel). 2021 Sep 27;10(10):
pubmed: 34681065
J Mol Neurosci. 1995;6(4):237-48
pubmed: 8860235
Int J Mol Sci. 2022 Nov 07;23(21):
pubmed: 36362415
J Sport Health Sci. 2020 Sep;9(5):394-404
pubmed: 32780691
Neurochem Res. 2016 Apr;41(4):892-904
pubmed: 26577396
Work. 2018;59(4):571-583
pubmed: 29733043
J Biomech. 2014 Jan 3;47(1):162-7
pubmed: 24157062
Am J Pathol. 2001 Apr;158(4):1345-54
pubmed: 11290552
Biomed Res Int. 2016;2016:2589276
pubmed: 27547756
Int J Alzheimers Dis. 2010 Jun 14;2010:
pubmed: 20798769
Front Mol Neurosci. 2017 Dec 19;10:427
pubmed: 29311817
Front Aging Neurosci. 2022 Jan 21;13:801828
pubmed: 35126091
Front Neurosci. 2018 Feb 07;12:55
pubmed: 29467614
J Funct Morphol Kinesiol. 2018 Mar;3(1):
pubmed: 30221205
J Cell Biol. 2018 Feb 5;217(2):459-472
pubmed: 29196460
Front Aging Neurosci. 2016 Jul 05;8:160
pubmed: 27458370
Neurochem Int. 2021 Jan;142:104926
pubmed: 33276022
Molecules. 2020 Dec 08;25(24):
pubmed: 33302541
Brain Stimul. 2020 Jul - Aug;13(4):1014-1023
pubmed: 32388044
J Alzheimers Dis. 2014;41(4):1177-92
pubmed: 24787919
Br J Ind Med. 1985 Feb;42(2):133-6
pubmed: 3970872
J Neurosci. 2010 Jan 6;30(1):372-81
pubmed: 20053918
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Dec 20;87(Pt A):126-146
pubmed: 28989099
Acta Neuropathol. 1999 Oct;98(4):345-8
pubmed: 10502038
Afr J Tradit Complement Altern Med. 2017 Jun 05;14(4):128-134
pubmed: 28638875
Brain Sci. 2021 Jan 10;11(1):
pubmed: 33435131
J Biol Chem. 2007 Aug 17;282(33):23818-28
pubmed: 17548355
Sci Rep. 2022 May 30;12(1):9020
pubmed: 35637277
Neuroscience. 2016 Mar 1;316:209-20
pubmed: 26742791
Sci Rep. 2018 Sep 19;8(1):14061
pubmed: 30232364
J Alzheimers Dis. 2019;68(2):609-624
pubmed: 30814360
Eur J Neurosci. 2007 Jan;25(2):406-16
pubmed: 17284181
Front Genet. 2014 Apr 23;5:88
pubmed: 24795750
Physiol Res. 2014;63(5):649-57
pubmed: 24908088
Front Pharmacol. 2012 Feb 10;3:14
pubmed: 22363284
Science. 2004 Apr 16;304(5669):448-52
pubmed: 15087549
Dose Response. 2018 Dec 04;16(4):1559325818811756
pubmed: 30574028
Obesity (Silver Spring). 2017 Oct;25(10):1745-1753
pubmed: 28840647
Transl Neurodegener. 2021 Sep 24;10(1):36
pubmed: 34560902